IRVINE, Calif., March 19, 2009 (GLOBE NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced its entry into the China market, further extending its presence in the global market. In addition to currently selling its products in more than 30 countries, SenoRx has begun marketing EnCor(r), its vacuum-assisted breast biopsy product, and its GelMark(tm) line of breast biopsy tissue markers through its distribution partner, Beijing Eastwide Medical Ltd (BJEW).
SenoRx has been steadily increasing its participation in selected international markets through a strategy of partnering with local in-country distributors who have breast imaging and/or interventional radiology franchises. BJEW is a major medical instrument and equipment distribution company in China focused on women's healthcare. With more than 20 years of experience, BJEW has assisted in building breast healthcare centers in major medical institutions and in regional medical facilities throughout the People's Republic of China.
"We are excited to enter the China market, which represents a continuation of our efforts to expand our international footprint in key markets where breast-care is increasingly becoming a national healthcare priority," said Lloyd Malchow, SenoRx President and Chief Executive Officer. "China remains one of the fastest growing economies in the world and has been devoting an increasing percentage of its gross domestic product (GDP) on improving healthcare for its people. Increasing awareness and detection of breast cancer in China has created a growing market for the latest minimally invasive vacuum-assisted breast biopsy technology."
Malchow continued, "We further believe that the addition of John Buhler, Vice President of Global Sales and Business Development, who joined the SenoRx team in 2008 and brings many years of experience in establishing distribution and support within China coupled with BJEW, will strengthen our prospects in this key growth market."
EnCor and SenoRx breast tissue biopsy markers have previously received regulatory clearances from China's State Food & Drug Administration (SFDA) and from countries within the European Economic Community and from all other countries that SenoRx has established distribution channels.
SenoRx has previously established partnering relationships with distributors in Australia, Austria, Belgium, Denmark, Egypt, Finland, France, Germany, Greece, Hong Kong, Iceland, Ireland, Italy, Luxembourg, Mexico, The Netherlands, Norway, Poland, Portugal, Russia, Saudi Arabia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, the United Arab Emirates and the United Kingdom.
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605
About Beijing Eastwide Medical Ltd
Beijing Eastwide Medical Ltd emerged from Eastwide Medical a company with 20 years of history and experience. BJEW leverages a knowledgeable staff that is well suited to working with experts and medical professionals in China. BJEW has provided support with building breast healthcare centers in major medical institutions and in regional medical facilities throughout China. While carrying a full line of breast healthcare products, ranging from screening to diagnosis, analysis and treatment equipment, BJEW also focuses on balancing advanced technology with market readiness when selecting new products for the Chinese market.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning international sales growth are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause SenoRx's actual results to differ materially from the statements contained herein. Information on potential risk factors that could affect SenoRx's business and its financial results are detailed in its most recent quarterly report on its Form 10-K, as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. SenoRx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.